Clinical IntraOp Announces Phase II Trial for Carcinoma Therapy

IntraOp Announces Phase II Trial for Carcinoma Therapy


IntraOp Medical Corporation has announced the second phase of the first-ever Electron FLASH Trial. For the first time, FLASH radiation will be compared to conventional radiotherapy to treat nonmelanoma skin cancer (NMSC). The experimental trial on humans is using IntraOp’s Mobetron electron-based linear accelerator (LINAC).

IntraOp has a platform to measure the Ultra-High Dose Rate (UHDR) radiation with electrons. Hence their system is being used globally. IntraOp empowers oncologists to offer the future of precision therapy by pioneering new radiation improvements. IntraOp, located in Sunnyvale, California, is a cancer treatment firm devoted to accelerating the cure.

Renowned FLASH researchers will lead the trial from Switzerland’s University Hospital of Lausanne who will be analyzing the safety and efficacy of local tumor control rates in patients with cutaneous squamous cell carcinomas.

The pros and cons of Ultra-High Dose Rate radiotherapy will be compared to conventional radiotherapy on the basis of two schemes: 22Gy single dose radiotherapy and 5 x 6Gy fractionated dose. The trial will be monitored for a period of 14 days, and patient applications are still open.

The Director of the Oncology Department of CHUV, J. Bourhis, believes that the trial will be an important milestone in determining the effectiveness of FLASH. The ongoing trials are considered an important landmark.

FLASH is a pre-clinical treatment technique that offers ultra-high dose rates of radiation therapy in less than seconds. Prior research indicates less toxicity, protection of healthy tissue, faster delivery than standard radiation, and fewer necessary fractionations. FLASH irradiation has been shown in pre-clinical studies to provide biological advantages and boost the therapeutic index by generating a protective effect for normal tissue.

IntraOp’s CEO, Sanjay Arora, appreciates the efforts being made by its partners at CHUV in leading the way toward FLASH. He further believes that with these efforts, Mobertron will continue to play an integral part in the process. This study may help strengthen the future of patient care.

CHUV pioneers innovation by providing global and in-house clinical trials committed to treating patients with the most up-to-date medical offerings. O. Gaide, R. Kinj, W. Jeanneret, F. Duclos, R. Moeckli, P. Jorge, and J. Bourhis are the study’s primary investigators. They represent CHUV as a multidisciplinary team from Lausanne University Hospital, radiation, and oncology. The Ultra-High Dose Rate for FLASH Radiotherapy is for research purposes only and has not been approved for sale by the United states regulators.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you